Novo Nordisk

In June 2024, Novo Nordisk was the most valuable company in Europe, worth about $640 billion, on the strength of two words the whole world knew: Ozempic and Wegovy. Eighteen months later it had shed roughly three-quarters of that value, lost its CEO, and guided to the first revenue decline in its modern history — while Eli Lilly became the first healthcare company on earth worth a trillion dollars. Everyone says Lilly simply had a better drug. That's true, and it's not the reason Novo lost.

The story is that Ozempic's 2017 diabetes approval made Novo stumble onto weight loss. The truth: Novo had already completed a 957-subject Phase 2 obesity trial before it launched its Phase 3 weight-management program. The real fork was never the science. It was whether it could build the factories.

The biggest pharma story of the decade ran on a drug approved only for diabetes. The cultural explosion was emergent, not engineered — and the same engine runs in reverse: stop the shot and two-thirds of the weight comes back.

In 2024 a Danish insulin company briefly became worth more than Denmark's entire GDP. The GLP-1 boom looks like luck. The real story is a 1926 ownership decision that let it spend a century compounding while rivals answered to quarterly shareholders.

The Ozempic story looks like a sudden conquest. It was the opposite: a U.S. entry that stalled at ~20% share for decades, carried by an ownership structure that doesn't have to answer to a quarter. That patience is now the liability.

A foundation that can't sell control and a plant that makes half the world's insulin look like a moat nothing can cross. But the GLP-1 franchise — Ozempic plus obesity care combined represent roughly 64% of FY2024 revenue — rests on one molecule whose core patent expired in 2026, and Lilly had already overtaken Novo to hold roughly 57% of the GLP-1 market by mid-2025.